4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Obsessive-Compulsive Disorder by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 89 ongoing clinical trials involving Obsessive-Compulsive Disorder
Of the 89 trials,34 trials are in Phase II
Furthermore, 24 trials are in Phase III

Number of ongoing Clinical Trials (for drugs) involving Obsessive-Compulsive Disorder by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Obsessive-Compulsive Disorder, a Central Nervous System condition. The largest number of ongoing clinical trials for Obsessive-Compulsive Disorder is conducted in the Asia-Pacific region. North America and Middle East and Africa are among some of the other prominent regions engaged in Obsessive-Compulsive Disorder-related drug trials.

Biohaven Pharmaceutical Holding Company Ltd: The leading ongoing Obsessive-Compulsive Disorder related clinical trial sponsor

Biohaven Pharmaceutical Holding Company Ltd is the top sponsor for Obsessive-Compulsive Disorder-related ongoing clinical trials.

Yale University, Iran University of Medical Sciences, Tehran University of Medical Sciences and Bangabandhu Sheikh Mujib Medical University are among other notable clinical trial sponsors involved in Obsessive-Compulsive Disorder. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Obsessive-Compulsive Disorder

Escitalopram oxalate (Lexapro/Cipralex/Entact/Esipram/Metopram, Sipralexa), Paroxetine hydrochloride (Paxil / Seroxat / Aropax/ Eutimil/ Motivan/ Frosinor/ Daboxanil) and Escitalopram oxalate (Lexapro/Cipralex/Entact/Esipram/Metopram, Sipralexa) are among the key marketed drugs involving Obsessive-Compulsive Disorder.

Escitalopram oxalate is the s-enantiomer of citalopram, phenylbutylamine derivative, acts as antidepressant agent. It functions via Sodium Dependent Serotonin Transporter Inhibitor mechanism of action. Escitalopram oxalate is formulated as tablets or film coated tablets, drops-solution and solution for oral route and injectable solution for intravenous route of administration. Escitalopram oxalate was first approved in 2001 and is marketed globally in the US, UK, China, Japan, Germany, and France by several prominent pharma giants including Allergan Sales LLC.

Paroxetine hydrochloride is an antidepressant agent. It functions via Sodium Dependent Serotonin Transporter Inhibitor mechanism of action. Paroxetine hydrochloride is formulated as film coated tablets, tablets, capsules, coated tablets and suspension for oral route of administration. Paroxetine hydrochloride was first approved in 1990 and is marketed globally in the US, UK, France, Germany, China and Japan by several prominent pharma giants including Apotex Corp.